Skip to main content
Huberman Lab

Essentials: Psychedelics for Treating Mental Disorders | Dr. Matthew Johnson

39 min episode · 2 min read
·
Matthew Johnson

Episode

39 min

Read time

2 min

Topics

Productivity, Product & Tech Trends, Psychology & Behavior

AI-Generated Summary

Key Takeaways

  • Therapeutic mechanism: Psychedelics dissolve rigid self-models by profoundly altering reality perception during sessions, allowing patients to experience agency differently—smokers realize they can simply decide to quit, depressed patients recognize they control their suffering beyond medical treatment.
  • Session protocol: Clinical psilocybin therapy involves cardiovascular and psychiatric screening to exclude schizophrenia and bipolar disorder, followed by preparation sessions building therapeutic rapport with guides, then 20-30mg doses administered in safe environments encouraging complete surrender to the experience.
  • Bad trip gateway: Approximately one-third of patients experience intense anxiety or fear of losing sanity during high-dose sessions, but this reality-shattering moment serves as the gateway to transcendental experiences when patients surrender rather than resist the dissolution of self.
  • Microdosing evidence: Peer-reviewed studies show no cognitive enhancement or sustained mood improvement from microdosing psychedelics. Some research indicates slight impairment in time perception and cognition, contradicting popular claims about productivity and creativity benefits from sub-perceptual doses.

What It Covers

Dr. Matthew Johnson explains how psychedelics like psilocybin and MDMA work through serotonin receptors to alter sense of self, enabling therapeutic breakthroughs in depression, PTSD, and addiction through carefully guided clinical sessions.

Key Questions Answered

  • Therapeutic mechanism: Psychedelics dissolve rigid self-models by profoundly altering reality perception during sessions, allowing patients to experience agency differently—smokers realize they can simply decide to quit, depressed patients recognize they control their suffering beyond medical treatment.
  • Session protocol: Clinical psilocybin therapy involves cardiovascular and psychiatric screening to exclude schizophrenia and bipolar disorder, followed by preparation sessions building therapeutic rapport with guides, then 20-30mg doses administered in safe environments encouraging complete surrender to the experience.
  • Bad trip gateway: Approximately one-third of patients experience intense anxiety or fear of losing sanity during high-dose sessions, but this reality-shattering moment serves as the gateway to transcendental experiences when patients surrender rather than resist the dissolution of self.
  • Microdosing evidence: Peer-reviewed studies show no cognitive enhancement or sustained mood improvement from microdosing psychedelics. Some research indicates slight impairment in time perception and cognition, contradicting popular claims about productivity and creativity benefits from sub-perceptual doses.

Notable Moment

Johnson describes a research participant who appeared to attempt diving through a painting on the wall during a session, genuinely believing she could enter another dimension—illustrating how psychedelics can temporarily override fundamental predictive models about physical reality.

Know someone who'd find this useful?

Episode Transcript

Welcome to Huberman Lab Essentials, where we revisit past episodes for the most potent and actionable science based tools for mental health, physical health, and performance. I'm Andrew Huberman, and I'm a professor of neurobiology and ophthalmology at Stanford School of Medicine. And now, my conversation with doctor Matthew Johnson. Well, Matthew, I've been looking forward to this for a long time. I'm a huge fan of your scientific work, and I'm here to learn from you. Likewise. Big fan and happy to do this with you. Alright. Well, thank you. My first question is a very basic one, which is what qualifies a substance to as a psychedelic? Nomenclature is a real challenge in this area of psychedelics. So starting with the word psychedelic, it just if if you're a pharmacologist, it's it's not very satisfying because that term really spans different pharmacological classes. In other words, if you're really concerned about receptor effects and the basic effects of a compound, it spans several com classes of compounds. But overall so it's really more of a a cultural term or, it does have a relationship to drug effects, but it's at the at at a very high level. So all of the so called psychedelics across these distinct, classes that I can talk more about. The way I put it is they all had the ability to profoundly alter one's sense of reality, and that can mean many things. Part of that is profoundly altering the sense of self, acutely. So when someone's on the psychedelic. So the different classes that can be the specific pharmacological classes that can be called a psychedelic are, one, the what are called the classic psychedelics. So in the literature, you'll see that term. And hallucinogen and psychedelic are all have traditionally been used synonymously. I think there was a little of a tendency to stay away from psychedelics because of the baggage, but there's been a return to that in the last several years. But the classic psychedelics or classic hallucinogens are things like LSD, psilocybin, which is in so called magic mushrooms. It's in over 200 species that we know of so far of mushrooms. Dimethyltryptamine or DMT, which is in dozens and dozens of plants. Mescaline, which is in the peyote cacti and some other cacti like San Pedro. And even amongst these classic psychedelics, there are two structural structural classes. So that's the chemistry. There's the tryptamine based compounds like psilocybin and DMT, and then there's the phenethylamine based compounds. So these are the basic two basic building blocks that that you're starting from, either a tryptamine structure or a phenethylamine structure. But that's just the chemistry that all of the what's more important, or at least to to someone like me, are the receptor effects, and then, ultimately, that's gonna have a relationship to the behavioral and subjective effects. So all of these classic psychedelics serve as agonist or partial agonist at the serotonin two way receptor, so …

Get the full transcript (6,705 words) + summary by email — free

One-time email with the complete transcript and AI summary of this episode. No account needed.

One email, no spam. We’ll also show you what SignalCast does.

Browse all Huberman Lab transcripts →

You just read a 3-minute summary of a 36-minute episode.

Get Huberman Lab summarized like this every Monday — plus up to 2 more podcasts, free.

Pick Your Podcasts — Free

Keep Reading

More from Huberman Lab

We summarize every new episode. Want them in your inbox?

Similar Episodes

Related episodes from other podcasts

Explore Related Topics

This podcast is featured in Best Health Podcasts (2026) — ranked and reviewed with AI summaries.

You're clearly into Huberman Lab.

Every Monday, we deliver AI summaries of the latest episodes from Huberman Lab and 192+ other podcasts. Free for one show.

Start My Monday Digest

No credit card · Unsubscribe anytime